Johnson Controls, a global multi-industrial company, is constantly focusing on improving the future of car seating. Thinking ahead, Johnson Controls will present its seating demonstrator vehicle SD15 to customers and media at the 66th Frankfurt Autoshow. The SD15 features a simulated vehicle environment with a focus on first- and second-row seating while addressing the three automotive megatrends from a seating perspective: autonomous driving, lightweight, and increasing customer demands towards individualization and style for future urban mobility.
Furthermore, the stylish ink jet printed seat covers of the SD15 show what Johnson Controls can do in terms of individualization. The weight and space saving multi-material seats padded with highly ergonomic foam parts pave the way towards the demands of lightweight design. Many SD15 features support the megatrend of autonomous driving in the future “multi-talented” vehicle seat.
The SD15’s front row features a power driver seat mounted to a curved track, eliminating the need for separate and complex mechanisms found in conventional seat arrangements. The seat offers a control console mounted directly to the seat structure that moves conveniently with the occupant, instead of being fixed between the seats which offers wireless charging options for mobile devices.
To view the multimedia release visit:
http://www.multivu.com/players/uk/7592351-johnson-controls-new-SD15-seating-vehicle/
iRobot Corp. (NASDAQ: IRBT), the leader in delivering robotic technology-based solutions, today announced the Roomba 980 vacuum cleaning robot – iRobot’s most capable and best cleaning robotic vacuum to date. Roomba 980 is the first Roomba to combine adaptive navigation with visual localization, cloud connected app control, and increased cleaning power on carpets, helping people to keep cleaner floors throughout the entire home at the push of a button.
“With more than 14 million robots in people’s homes worldwide, iRobot is the global leader in automated home cleaning,” said Colin Angle, chairman and chief executive officer of iRobot. “Roomba 980 is the next big step as it marks iRobot’s first cloud connected product with mapping capabilities for the consumer market. Leveraging the cloud and mapping technologies, robots gain a better understanding of their environment, and customers are provided with more control. Looking ahead, these technologies will also enable expanded capabilities for connected robots in the smart home.”
“Vacuum cleaning robots can’t rely on any one feature or technology to clean effectively,” said Christian Cerda, executive vice president and general manager of iRobot’s Home Robots business unit. “Vacuum performance, efficient navigation, adapting to ever-changing environments and cleaning under furniture where dirt is hiding are all important factors, and they must be balanced. Roomba 980 takes this into account to deliver convenient, customized, powerful cleaning assistance, each and every day.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7625951-irobot-roomba-980-vacuum-cleaning-robot/
Bringing developers advanced integration, scalability and peripherals all in one chip, Texas Instruments (TI) (NASDAQ: TXN) today announced the Sitara™ AM57x processor family, the highest performance devices in this processor platform. Sitara AM57x processors are designed for a broad range of embedded and industrial applications through their unique heterogeneous architecture including ARM® Cortex®-A15 cores for high-performance processing and running a high-level operating system (HLOS). Additionally, AM57x processors integrate TI’s C66x digital signal processors (DSPs) for analytics and real-time computation, programmable real-time units (PRU) and ARM Cortex-M4 cores for control functions, and video and graphic accelerators for advanced user interfaces and multimedia applications, making the AM57x processors unmatched in their class.
The new Sitara AM57x family of processors was designed from the ground up with high performance and integration in mind. As a result, the processors bring developers unparalleled performance of more than 40 percent greater than quad-core ARM Cortex-A9 processors and 280 percent greater than standard dual-core ARM Cortex-A9 processors found in the broad embedded market.
To view the multimedia release go to:
http://www.multivu.com/players/English/70647530-ti-sitara-am57x-processor/
In an effort to inform children and their families about the importance of food safety, U.S. Department of Agriculture (USDA) and the Ad Council are joining 20th Century Fox to launch a series of public service advertisements (PSAs) featuring footage from the upcoming film Alvin & the Chipmunks: The Road Chip.
An estimated 1 in 6 (48 million) Americans get sick from foodborne illness each year, resulting in roughly 128,000 hospitalizations and 3,000 deaths, according to the Centers for Disease Control and Prevention. Children are among the most vulnerable to food poisoning because their immune systems are still developing, so parents and caregivers need to take extra precautions when preparing food for children under five.
The new PSAs, featuring everyone’s favorite Chipmunks – Alvin, Simon, and Theodore – highlight the four food safety steps consumers can use to prevent foodborne illness. The Chipmunks’ antics and hilarious situations in which they find themselves provide a perfect platform to illustrate these four steps: Clean, Separate, Cook, and Chill. The PSAs help explain actions anyone can take to safely prepare their food, using the Chipmunks as the tool to bring fun and relevancy to a serious topic. The partnership includes TV, radio, out-of-home and web advertising, and parents and children can also find kid-friendly activities that further reinforce the food safety steps by visiting FoodSafety.gov.
To view the multimedia release go to:
http://www.multivu.com/players/English/7652251-ad-council-food-safety/
The following is being released by the Notice Provider, Kinsella Media, LLC, about the lawsuit In re Automotive Parts Antitrust Litigation, MDL No. 2311.
Settlements totaling approximately $54.1 million have been reached with two Defendants. The lawsuits allege that they fixed the price of certain motor vehicle components, causing millions of consumers and businesses from around the country to overpay for new or leased automobiles and replacement parts, such as air flow meters, alternators, ATF warmers, electronic throttle bodies, fuel injection systems, ignition coils, inverters, motor generators, radiators, starters, and valve timing control devices.
The Settlements provide monetary relief for consumers in the District of Columbia and 30 states - Arizona, Arkansas, California, Florida, Hawaii, Iowa, Kansas, Maine, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, Oregon, Rhode Island, South Carolina, South Dakota, Tennessee, Utah, Vermont, West Virginia, and Wisconsin. The Settlements also provide non-monetary relief, including cooperation, and an agreement by the Defendants not to engage in certain conduct for a period of 24 months.
To view the multimedia release go to:
http://www.multivu.com/players/English/7666751-auto-parts-antitrust-litigation/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Teaming up with the American Diabetes Association® and the multi-talented performer and caretaker Joey Fatone @RealJoeyFatone, Colgate Total® is using the power of laughter to help raise awareness of the potential link between oral health and diabetes with the new “30 Days of Laughter” campaign (#30DaysofLOL), beginning today. The 30 days from November 12 to December 11, 2015 will be filled with laugh-out-loud videos, funny social media posts, engaging apps and more to make the diabetes community laugh, all while building awareness of the importance of maintaining the health of the teeth and gums behinds those smiles.
According to the Centers for Disease Control and Prevention, people with diabetes are two times more likely to develop gum disease1. Colgate Total® toothpaste can help prevent and even reverse gingivitis, the most common form of gum disease. It is the only FDA-approved and American Dental Association-accepted2 toothpaste to help prevent gingivitis. With regular twice daily brushing, you can help improve your gum health in as little as four weeks3 with Colgate Total®.
Understanding how challenging managing diabetes can sometimes be, the funny and talented performer Joey Fatone is leading the “30 Days of Laughter” campaign to remind people that sometimes laughter can feel like the best medicine. “When my father was diagnosed with Type 2 diabetes, our family was shocked. But we’re a big, loving group and we all help him together every day. I know that humor in the face of challenges is vital and I’m excited to share that with other families touched by diabetes.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7654951-colgate-30-days-of-laughter/
With the onset of winter season in the country, breathing problems and respiratory diseases will also be on the rise. To ensure that patients with respiratory problems breathe with ease, a comprehensive patient Mobile App named “My Breathefree” has been launched as a virtual caregiver by ‘Breathefree’, a public service initiative by Cipla. This app is specifically designed for Indian conditions and is available on Google play store and iOS platform for all patients, caregivers and doctors.
One of the major chronic respiratory problems in the country is asthma and “My Breathefree” app will be a great help towards better asthma management and control. Asthma causes limitations in daily activities, loss of school and work days, lung function impairment, reduced quality of life and an adverse socioeconomic burden. However, if monitored and treated properly, asthmatics can control their disease and lead an absolutely normal and healthy life.
To view the multimedia release go to:
http://www.multivu.com/players/English/7562351-lung-care-asthma-mobile-app/
Losing weight and being healthier are at the top of everyone’s New Year’s resolutions. But, despite the best intentions, work, kids, and social events often push lifestyle changes to the bottom of the list. While many are familiar with type 2 diabetes, fewer are aware of prediabetes, a serious health condition that affects 86 million Americans (more than 1 in 3) and often leads to type 2 diabetes. People with prediabetes have higher than normal blood glucose (sugar) levels, but not high enough yet to be diagnosed with type 2 diabetes.
To raise awareness and help people with prediabetes know where they stand and how to prevent type 2 diabetes, the American Diabetes Association (ADA), the American Medical Association (AMA), and the Centers for Disease Control and Prevention (CDC) have partnered with the Ad Council to launch the first national public service advertising (PSA) campaign about prediabetes. The PSA campaign, featuring first-of-its-kind communications techniques, was developed pro bono by Ogilvy & Mather New York for the Ad Council.
Nearly 90 percent of people with prediabetes don’t know they have it and aren’t aware of the long-term risks to their health, including type 2 diabetes, heart attack, and stroke. Current trends suggest that, if not treated, 15 to 30 percent of people with prediabetes will develop type 2 diabetes within five years. The good news is that prediabetes often can be reversed through weight loss, diet changes and increased physical activity. Diagnosis is key: research shows that once people are aware of their condition, they are much more likely to make the necessary lifestyle changes.
To view the multimedia release go to:
http://www.multivu.com/players/English/7731551-ad-council-prediabetes-psa/
More than 15 percent of reproductive-aged women have filled a prescription for an antidepressant medication during the years 2008–2013, according to a new analysis published today in the Centers for Disease Control and Prevention (CDC)’s Morbidity and Mortality Weekly Report (MMWR).
January is National Birth Defects Prevention Month and the CDC is working with the March of Dimes to raise awareness about the use of antidepressant medications by women of reproductive age, and what women should know and do for their own health and that of their babies. There is conflicting evidence about the potential link between some antidepressants and certain birth defects. Some commonly used antidepressants are sertraline (Zoloft), bupropion (Wellbutrin, Zyban), and citalopram (Celexa).
To view the multimedia release go to:
http://www.multivu.com/players/English/7709851-march-of-dimes-antidepressant-pregnancy-study/
